Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$33.38+0.40 (+1.21%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%
Castle Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Castle Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was $39.74M, down 35.7% year over year. For fiscal 2025 it was $64.35M, down 0.8% from the year before. The highest annual figure on record is $64.87M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.35M | -0.8% |
| FY2024 | Dec 31, 2024 | $64.87M | – |
| FY2023 | Dec 31, 2023 | -$5.63M | – |
| FY2022 | Dec 31, 2022 | -$41.66M | – |
| FY2021 | Dec 31, 2021 | -$18.98M | -292.4% |
| FY2020 | Dec 31, 2020 | $9.87M | +40.6% |
| FY2019 | Dec 31, 2019 | $7.02M | – |
| FY2018 | Dec 31, 2018 | -$12.30M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.74M | -12.8% |
| Q2 FY2026 | Jun 30, 2026 | $15.20M | -27.0% |
| Q1 FY2026 | Mar 31, 2026 | -$22.13M | – |
| Q4 FY2025 | Dec 31, 2025 | $26.93M | +10.5% |
| Q3 FY2025 | Sep 30, 2025 | $22.63M | -3.0% |
| Q2 FY2025 | Jun 30, 2025 | $20.82M | -13.2% |
| Q1 FY2025 | Mar 31, 2025 | -$6.04M | – |
| Q4 FY2024 | Dec 31, 2024 | $24.37M | +31.1% |
| Q3 FY2024 | Sep 30, 2024 | $23.34M | +365.6% |
| Q2 FY2024 | Jun 30, 2024 | $24.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.84M | – |
| Q4 FY2023 | Dec 31, 2023 | $18.59M | – |
| Q3 FY2023 | Sep 30, 2023 | $5.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.44M | -147.7% |
| Q1 FY2021 | Mar 31, 2021 | -$3.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$430.00K | -109.6% |
| Q3 FY2020 | Sep 30, 2020 | -$2.96M | -493.0% |
| Q2 FY2020 | Jun 30, 2020 | $13.50M | +2701.0% |
| Q1 FY2020 | Mar 31, 2020 | -$251.00K | -119.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.49M | – |
| Q3 FY2019 | Sep 30, 2019 | $752.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $482.00K | – |
| Q1 FY2019 | Mar 31, 2019 | $1.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.21M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.88M | – |
See a number that looks wrong?